Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
7.85
-0.16 (-2.00%)
Nov 4, 2024, 4:00 PM EST - Market closed
Acrivon Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 24.05 | 21.08 | 8.71 | 2.47 | 1.3 |
| Research & Development | 52.24 | 46.02 | 23.95 | 13.72 | 1.87 |
| Operating Expenses | 76.3 | 67.1 | 32.66 | 16.18 | 3.17 |
| Operating Income | -76.3 | -67.1 | -32.66 | -16.18 | -3.17 |
| Interest & Investment Income | 0.56 | - | - | - | 0.03 |
| Other Non Operating Income (Expenses) | 3.41 | 3.39 | 0.79 | -0.06 | -0.07 |
| EBT Excluding Unusual Items | -72.33 | -63.71 | -31.87 | -16.24 | -3.21 |
| Gain (Loss) on Sale of Investments | 3.32 | 3.32 | 0.7 | - | - |
| Other Unusual Items | - | - | - | - | -2.1 |
| Pretax Income | -69 | -60.39 | -31.17 | -16.24 | -5.31 |
| Net Income | -69 | -60.39 | -31.17 | -16.24 | -5.31 |
| Net Income to Common | -69 | -60.39 | -31.17 | -16.24 | -5.31 |
| Shares Outstanding (Basic) | 26 | 22 | 4 | 2 | 1 |
| Shares Outstanding (Diluted) | 26 | 22 | 4 | 2 | 1 |
| Shares Change (YoY) | 81.46% | 435.63% | 136.43% | 21.70% | - |
| EPS (Basic) | -2.68 | -2.74 | -7.56 | -9.32 | -3.70 |
| EPS (Diluted) | -2.68 | -2.74 | -7.56 | -9.32 | -3.70 |
| Free Cash Flow | -55.26 | -43.93 | -32.28 | -14.22 | -2.82 |
| Free Cash Flow Per Share | -2.14 | -1.99 | -7.83 | -8.16 | -1.97 |
| EBITDA | -75.56 | -66.57 | -32.29 | -16.15 | -3.16 |
| D&A For EBITDA | 0.73 | 0.54 | 0.36 | 0.04 | 0.01 |
| EBIT | -76.3 | -67.1 | -32.66 | -16.18 | -3.17 |
Source: S&P Capital IQ. Standard template.
Financial Sources.